

1 Title

2 Monitoring transmission intensity of trachoma with serology

3

4 Author List

5 Christine Tedijanto¹, Anthony W. Solomon², Diana L. Martin³, Scott D. Nash⁴, Jeremy D.
6 Keenan^{1,5}, Thomas M. Lietman^{1,5,6,7}, Patrick J. Lammie⁸, Kristen Aiemjoy⁹, Abdou Amza^{10,11},
7 Solomon Aragie^{1,12,13}, Ahmed M. Arzika¹⁴, E. Kelly Callahan⁴, Sydney Carolan¹, Adisu Abebe
8 Dawed¹⁵, E. Brook Goodhew³, Sarah Gwyn³, Jaouad Hammou¹⁶, Boubacar Kadri^{10,11},
9 Khumbo Kalua¹⁷, Ramatou Maliki¹⁴, Beido Nassirou^{10,11}, Fikre Seife¹⁸, Zerihun Tadesse¹²,
10 Sheila K. West¹⁹, Dionna M. Wittberg¹, Taye Zeru²⁰, Benjamin F. Arnold^{1,5*}

11

12 * Corresponding Author:

13 Benjamin F. Arnold, PhD

14 Associate Professor

15 F.I. Proctor Foundation

16 University of California, San Francisco

17 ben.arnold@ucsf.edu

18

19 Affiliations

20 ¹ Francis I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA,
21 94158

22 ² Global Neglected Tropical Diseases Programme, World Health Organization, Geneva, Switzerland

23 ³ Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA,
24 USA 30329

25 ⁴ The Carter Center, Atlanta, GA, USA, 30307

26 ⁵ Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA,
27 94158

28 ⁶ Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA
29 94143

30 ⁷ Department of Epidemiology and Biostatistics, University of California San Francisco, San
31 Francisco, CA 94143

32 ⁸ Neglected Tropical Diseases Support Center, Task Force for Global Health, Atlanta, GA, USA,
33 30030

34 ⁹ Division of Epidemiology, Department of Public Health Sciences, University of California Davis
35 School of Medicine, Davis, CA, USA

36 ¹⁰ Programme National de Santé Oculaire, Niamey, Niger

37 ¹¹ Programme National de Lutte Contre la Cecité, Niamey, Niger

38 ¹² The Carter Center Ethiopia, Addis Ababa, Ethiopia

39 ¹³ Infection Biology, Addis Ababa University, Addis Ababa, Ethiopia

40 ¹⁴ The Carter Center Niger, Niamey, Niger

41 ¹⁵ Amhara Regional Health Bureau, Bahir-Dar, Ethiopia

42 ¹⁶ Service of Ocular and Otological Diseases, Epidemiology and Disease Control Directorate, Ministry
43 of Health, Morocco

44 ¹⁷ Blantyre Institute for Community Outreach, Malawi

45 ¹⁸ Federal Ministry of Health, Addis Ababa, Ethiopia

46 ¹⁹ Johns Hopkins School of Medicine, Dana Center for Preventive Ophthalmology, Wilmer Eye
47 Institute, Baltimore MD USA

48 ²⁰ Amhara Public Health Institute, Bahir-Dar, Ethiopia

49

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

50 **Abstract**

51

52 Trachoma, caused by ocular *Chlamydia trachomatis* infection, is targeted for global
53 elimination as a public health problem by 2030. To provide evidence for use of
54 antibodies to monitor *C. trachomatis* transmission, we collated IgG responses to
55 Pgp3 antigen, PCR positivity, and clinical observations from 19,811 children aged 1–
56 9 years in 14 populations. We demonstrate that age-seroprevalence curves
57 consistently shift along a gradient of transmission intensity: rising steeply in
58 populations with high levels of infection and active trachoma and becoming flat in
59 populations near elimination. Seroprevalence (range: 0–54%) and seroconversion
60 rates (range: 0–15 per 100 person-years) correlate with PCR prevalence (r : 0.87,
61 95% CI: 0.57, 0.97). A seroprevalence threshold of 13.5% (seroconversion rate 2.75
62 per 100 person-years) identifies clusters with any PCR-identified infection at high
63 sensitivity (>90%) and moderate specificity (69-75%). Antibody responses in young
64 children provide a robust, generalizable approach to monitor population progress
65 toward and beyond trachoma elimination.

66

67 Introduction

68 Trachoma is the leading infectious cause of blindness and has been targeted for
69 elimination as a public health problem by 2030.¹ Caused by repeated infections with
70 the bacterium *Chlamydia trachomatis*, trachoma has historically been monitored via
71 district-level estimates of clinical signs.² However, clinical signs may not align well
72 with transmission intensity, particularly after mass drug administration of
73 azithromycin (MDA)^{3–5}, and are prone to measurement error, especially as cases
74 become rare.^{6–8} As a result, there has been growing interest in IgG antibody
75 responses as an objective and easy-to-collect biomarker to inform control programs.
76 Based on examples from other infectious diseases including malaria⁹ and SARS-
77 CoV-2,¹⁰ use cases for trachoma serology may include monitoring population-level
78 transmission to determine appropriate interventions, post-validation surveillance,
79 opportunistic investigation of populations using blood collected for other purposes,
80 and fine-scale geographic targeting of control measures.^{11–13}

81
82 IgG antibody responses to *C. trachomatis* antigens Pgp3 and CT694 are sensitive
83 and specific markers of *C. trachomatis* infection.^{14,15} Assays have demonstrated
84 consistency across platforms (multiplex bead, enzyme-linked immunosorbent, lateral
85 flow),^{16–18} robust seropositivity cutoffs,¹⁹ and high repeatability.^{18,20} Of the two
86 antigens, Pgp3 appears to elicit a stronger and more durable response and is
87 collected in most trachoma serology surveys.²¹ In epidemiologic studies,
88 investigators have observed alignment between population-level summaries of
89 antibody response and other trachoma markers, including the presence of *C.*
90 *trachomatis* DNA, as determined by PCR, and the active trachoma sign
91 trachomatous inflammation—follicular (TF). Individual studies suggest age-
92 dependent seroprevalence curves rise steeply with age among children in trachoma-
93 endemic communities^{14,15} and are flat in communities that have eliminated
94 trachoma.^{22–24} IgG responses to Pgp3 can be measured from dried blood spots and
95 have the potential to be scaled through integration in multiplex surveillance
96 strategies with other infectious pathogens.²⁵ Key next steps to advance the use of
97 serology to monitor trachoma programs are to benchmark serology against
98 independent measures of transmission, notably PCR, and to formalize the analytic
99 approaches used to summarize trachoma antibody data.

100
101 Here, we collated IgG antibody, infection, and clinical data from 14 populations in
102 five countries across a gradient of trachoma transmission intensities that ranged
103 from hyper-endemic to post-elimination. Due to the shortcomings of clinical signs, we
104 used PCR as the primary marker of trachoma activity, with TF as a secondary
105 indicator to contextualize serologic estimates. We hypothesized that population-level
106 summaries of trachoma antibody measurements would follow a consistent path
107 toward elimination, characterized by flattening of age-seroprevalence curves and a
108 corresponding decline in seroconversion rates. We also hypothesized that different
109 seroepidemiologic summary measures (e.g. seroprevalence, seroconversion rates)

110 would be consistent with one another and align similarly with population-level
111 transmission. We completed a series of analyses to test these hypotheses and in
112 doing so, develop robust analytic methods for trachoma serology as we approach
113 the elimination endgame.

114

115 **Results**

116 **Study populations and settings**

117 We combined serologic, molecular, and clinical measurements collected between
118 2012 and 2019 across nine studies in five countries (**Supplementary Table 1**).^{26–38}
119 When possible, measurements within the same study were stratified into populations
120 corresponding to trachoma evaluation units, resulting in 14 study populations. All
121 studies were conducted in Africa and represented a gradient of trachoma
122 transmission from hyper-endemic transmission to post-elimination. Measurements
123 were taken at a single time point or in repeated cross-sectional visits (typically
124 annual measurements). Due to changing transmission and/or interventions over time
125 in some studies, analyses included only the most recent round of measurements for
126 each population. We analyzed sampling clusters with 15 or more serologic
127 measurements, a total of 459 clusters. The median number of children contributing
128 information per cluster was 40 (interquartile range: 32–47) (**Supplementary Fig. 1**),
129 for a total of 19,811 serologic measurements. Eleven studies included children aged
130 1–9 years, and three studies focused on children aged 1–5 years (**Supplementary**
131 **Fig. 2**).

132

133 We generated population-level summaries using the median and range across
134 clusters and observed wide variation in seroprevalence (median: 8%; range: 0–
135 54%), PCR prevalence (median: 3%; range: 0–26%), and TF prevalence (median:
136 6%; range: 0–56%) (**Fig. 1**). PCR, a measure of current infection, may disappear
137 rapidly following MDA³⁹. Among clusters with MDA in the past year, the median PCR
138 prevalence was 0%, while among clusters without recent MDA, PCR prevalence was
139 12%. Cluster-level estimates within the same population were often variable, likely a
140 combination of heterogeneity in disease transmission and stochasticity due to
141 smaller sample sizes. Across the gradient of transmission intensities, population-
142 level summaries of seroprevalence aligned with PCR and TF prevalence (**Fig. 1**).

143

144 **Charting progress toward elimination with serology**

145 We estimated age-dependent seroprevalence curves using semiparametric splines
146 and seroconversion rates from age-structured seroprevalence (Methods). Across
147 populations, seroconversion rates ranged from 0 to 15 per 100 person-years
148 (median: 1.7) using a catalytic model without seroreversion (**Fig. 2**). Consistent with
149 our hypothesis, we observed that age-seroprevalence curves were flatter and
150 seroconversion rates were lower in areas with lower PCR prevalence. Age-
151 seroprevalence curves rose steeply in settings with high levels of infection such as
152 Wag Hemra and Andabet, Ethiopia, reaching >50% seroprevalence by age 9 years.

153 In contrast, in populations with flatter curves (<10% seroprevalence by age 9 years,
154 seroconversion rate <1 per 100 person-years), PCR prevalence was 0% when
155 measured (Woreta town and Alefa, Ethiopia). Among populations with moderately
156 increasing age-seroprevalence curves, roughly corresponding to seroconversion
157 rates between 1 and 5 per 100 person-years, PCR prevalence ranged from 0 (Dera,
158 Ethiopia) to 1.9% (Kongwa, Tanzania 2018).

159

160 **Agreement between serology-based summary measures**

161 Summary statistics estimated from age-seroprevalence curves provide additional,
162 useful summary measures of transmission.^{9,40} Population-level summaries of IgG
163 responses include geometric mean IgG levels, seroprevalence, and seroconversion
164 rates — each progression from IgG levels to seroconversion rates relies on
165 additional model assumptions and analysis complexity (details in Methods). In the
166 estimation of seroconversion rates from age-structured seroprevalence, we
167 considered a range of model complexity that included a catalytic model
168 (corresponding to a susceptible-infected-recovered, SIR, model), a reversible
169 catalytic model allowing for seroreversion (corresponding to a susceptible-infected-
170 susceptible, SIS, model), and a semiparametric hazard model that allowed for age-
171 varying seroconversion rates.

172

173 A key question for elimination programs is whether the additional complexity in
174 analysis leads to more useful information for identifying populations with ongoing
175 ocular *C. trachomatis* transmission. We estimated each summary at the sampling
176 cluster and population levels across the 14 study populations and found high
177 correlation between all measures (Spearman $\rho \geq 0.88$ for all comparisons, **Fig. 3**).
178 Cluster-level seroprevalence was strongly, linearly related with geometric mean IgG
179 levels on the \log_{10} scale (**Fig. 3a**), and there was a strong, non-linear relationship
180 between seroprevalence and the seroconversion rate (**Fig. 3b**). Catalytic models
181 that allowed for seroreversion shifted seroconversion rates up, particularly for
182 clusters with a seroconversion rate greater than 20 per 100 person-years but had
183 minimal influence on estimates at intermediate and lower levels of transmission (**Fig.**
184 **3c**). Similarly, seroprevalence was tightly linked with seroconversion rates that
185 allowed for seroreversion in settings with lower prevalence, and greater dispersion
186 was observed in hyperendemic populations (**Fig. 3d**). The most complex model, a
187 semiparametric proportional hazards spline model that allowed for an age-varying
188 seroconversion rate, required more data than would be typically available at the
189 sampling cluster level and thus could only be estimated at the population level where
190 its estimates aligned closely with a simpler, constant rate model (**Supplementary**
191 **Fig. 3**). These results show that all serologic summary measures provide similar
192 information when averaged at the cluster or population level across all ranges of
193 transmission and particularly at lower levels of transmission.

194

195 **Comparing trachoma indicators in the presence and absence of MDA**

196 As most trachoma program interventions act to clear infection or reduce its
197 transmission, we sought summaries that could capture variation in populations' *C.*
198 *trachomatis* infection burden. Seroprevalence and PCR prevalence aligned closely
199 at the population level ($r = 0.87$; 95% CI: 0.57–0.97, **Fig. 4a**). At both the cluster- and
200 population-levels, seroprevalence was almost always greater than or equal to PCR
201 prevalence, underscoring the sensitivity of seroprevalence as a measure of current
202 or past infection. However, PCR prevalence was highly variable across levels of
203 seroprevalence; low PCR prevalence in the context of high seroprevalence may
204 imply previously high levels of infection that had been controlled by MDA or other
205 interventions. Relationships between TF and PCR prevalence were similar
206 (population-level $r = 0.92$; 95% CI: 0.70–0.98, **Fig. 4b**).

207
208 As shown in prior work,⁴¹ TF and seroprevalence were more strongly correlated with
209 PCR prevalence in the absence of MDA in the past year (**Fig. 4a, 4b**). In the
210 absence of MDA, the relationship between seroprevalence and PCR prevalence was
211 nearly linear, particularly in high transmission settings. In the presence of recent
212 MDA, correlations between trachoma indicators weakened presumably because IgG
213 and TF prevalence remain elevated as durable indicators of trachoma even after
214 infections have been reduced through MDA.

215
216 We also stratified the analyses by child age and observed similar correlations
217 between indicators among children aged 1–9 years compared to children aged 1–5
218 years (**Fig. 5**). When summarizing IgG responses as seroconversion rate instead of
219 seroprevalence, overall results and subgroup results by recent MDA and age group
220 were similar (**Supplementary Fig. 4**), reflecting the tight correlation between
221 serologic summaries (**Fig. 3**). Our results show that serologic summaries align with
222 PCR prevalence as well or better than TF, the current programmatic indicator, and
223 that serology performs well even among preschool aged children. In populations that
224 have recently undergone MDA, IgG and TF will likely remain elevated even as
225 infection prevalence falls.

226 227 **Assessing serologic thresholds for elimination of infections**

228 Due to the wide variability in trachoma indicators both within and between
229 populations, we used a nonparametric approach to evaluate potential serologic
230 summary thresholds. Based on the alignment between seroprevalence and PCR at
231 the cluster level and the relatively large number of clusters, we assessed sensitivity
232 and specificity using cluster-level values. At each potential threshold, sensitivity and
233 specificity were calculated across the 281 clusters with PCR measurements, 112 of
234 which had at least one infection detected by PCR. Although presence of a single
235 infection is a stringent threshold, an appropriate level of PCR prevalence required to
236 prevent blindness due to trachoma has yet to be established. Under this definition, a
237 threshold with high sensitivity would result in more infected clusters being detected,
238 while a threshold with high specificity might imply less unnecessary intervention.

239 While overtreatment should be avoided, we focused on thresholds with high
240 sensitivity with the goal of elimination in mind.

241
242 There was good classification of clusters with and without *C. trachomatis* infections
243 based on either seroprevalence or seroconversion rates (AUC=0.92). Thresholds of
244 13.5% seroprevalence (**Fig. 6**) or 2.75 seroconversions per 100 person-years
245 (**Supplementary Fig. 5**) had 90% sensitivity and 69-75% specificity to identify
246 clusters with any PCR-detected infections. Thresholds of 22.5% seroprevalence and
247 5.75 seroconversions per 100 person-years had 80% sensitivity and 92-93%
248 specificity. Thresholds were conservative when compared against population-
249 specific sensitivity estimates in high transmission settings, but sensitivity dropped
250 quickly in lower transmission populations with few infected clusters (n=4 in
251 Chikwawa, Malawi and n=6 in Mchinji, Malawi) (**Fig. 6a**).

252
253 In a sensitivity analysis we repeated the approach including only children aged 1–5
254 years, since restricting to younger ages should result in overall lower seroprevalence
255 and potentially different seroconversion rates. We found classification of clusters
256 with and without *C. trachomatis* infections was almost identical to the main analysis
257 (AUC=0.92), and thresholds of 12.5% seroprevalence and 2.75 conversions per 100
258 person-years had 90% sensitivity and 69-71% specificity to identify clusters with any
259 PCR-detected infections (**Supplementary Fig 6**).

260
261 In a supplementary assessment of the thresholds, we applied them to populations
262 with very low trachoma prevalence that were not included in the threshold analysis
263 because cluster-level PCR results were unavailable (Dosso, Alefa, and Woreta town,
264 see **Figs. 1** and **2**). District-level PCR from Alefa and Woreta town, Ethiopia were
265 estimated to be 0%, and a recent study from the same population in Dosso, Niger
266 found no *C. trachomatis* in pooled metagenomic testing of ocular swabs.³⁸ In these
267 three populations, 98% of clusters (60/61) fell below the serologic thresholds for 90%
268 sensitivity, supporting the interpretation of low levels of infection below the estimated
269 thresholds.

270

271 **Discussion**

272 Using antibody measurements from 14 populations across a gradient of *C.*
273 *trachomatis* transmission intensity, we demonstrated that IgG Pgp3 age-
274 seroprevalence curves flatten and seroprevalence and seroconversion rates
275 progress toward zero as populations approach elimination, consistent with biological
276 assumptions and observations across other pathogens.^{40,42} To our knowledge, this is
277 the largest synthesis of *C. trachomatis* serology and infection data spanning globally
278 relevant transmission settings from hyper-endemic to elimination. Summaries of IgG
279 responses to *C. trachomatis* antigen Pgp3 among children aged 1–9 years aligned
280 similarly with PCR prevalence and with one another at both the cluster- and
281 population-levels, indicating that cluster-level Pgp3 summaries reflect variation in *C.*

282 *trachomatis* infections and ongoing transmission. Combining information across all
283 populations, we found that thresholds of 13.5% seroprevalence and 2.75
284 seroconversions per 100 person-years identified clusters with any infection with high
285 sensitivity (>90%) and moderate specificity (69 to 75%). We observed similar results
286 when analyses were restricted to children aged 1–5 years, an age group that is
287 potentially easier to sample in household surveys as they are not yet in school.

288
289 We demonstrated that seroprevalence and seroconversion rates perform as well or
290 better as correlates of population levels of infection compared with clinical TF, and
291 serology is arguably more objective, granular, and scalable for surveillance.
292 Although clinical signs are important markers of disease progression, MDA is
293 targeted towards *C. trachomatis* infections — if clinical signs continue to be present
294 in the absence of antibody responses, further investigation may be warranted to
295 determine other potential causes of inflammation. Compared to PCR, which also
296 measures *C. trachomatis* infections, serology is cost-effective, with simpler collection
297 procedures and the opportunity to leverage banked samples, and measures
298 exposure over time versus at a single point, an advantage in low prevalence
299 settings.

300
301 By focusing on parsimonious, generalizable methods, our aim was to present
302 seroepidemiologic approaches that could be easily applied and interpreted by
303 trachoma control programs. Trachoma programs currently rely on district-level
304 estimates of active trachoma, and this analysis may be extended to develop district-
305 level thresholds as an increasing number of district-level, population-based serologic
306 surveys become available. Cluster-level estimates, as investigated here, may be a
307 promising alternative to identify focal areas for intervention, particularly in
308 combination with geostatistical methods to improve precision and project across
309 unsurveyed regions.⁴³

310
311 Programmatic decisions related to suspension or reinitiation of antibiotic MDA
312 primarily take place in low to intermediate transmission settings, and this study
313 demonstrates that the information serologic surveillance provides in such settings
314 should be robust to choice of summary statistic. Serologic summaries of increasing
315 complexity were tightly correlated with one another, and the relationship was nearly
316 linear in settings with low to intermediate transmission (**Fig. 3**). Quantitative IgG
317 responses potentially provide information at very low levels of *C. trachomatis*
318 transmission when most children are seronegative,⁴⁴ but a challenge is that IgG
319 responses are in arbitrary units that may not be directly comparable across studies.
320 Members of our team recently developed a chimeric, monoclonal antibody to help
321 facilitate direct comparison of quantitative antibody levels across studies.¹⁸
322 Seroprevalence and seroconversion rates are standard transformations of the
323 quantitative IgG response that are easier to compare across studies and labs. A
324 potential drawback of seroprevalence and seroconversion is that they may be
325 sensitive to choice of the seropositivity cutoff, potentially affecting programmatic

326 decisions based on thresholds. In a sensitivity analysis, we found that identification
327 of clusters with *C. trachomatis* infection based on seroprevalence and
328 seroconversion rates were robust to large changes in the seropositivity cutoff
329 (**Supplementary Fig 7**). The seroconversion rate is tightly linked to the slope of the
330 age-seroprevalence curve (details in Methods). Additionally, the seroconversion rate
331 implicitly adjusts for age (not guaranteed with mean IgG or seroprevalence) and can
332 be interpreted as a measure of a pathogen's force of infection. Although we did not
333 consider complicated seroconversion models that allowed for changes in
334 transmission over time, such complexity may be less relevant when analyzing
335 measurements from young children because their antibody responses reflect recent
336 infections.⁴⁵⁻⁴⁷

337
338 Our results support estimation of age-seroprevalence curves among young children
339 combined with estimation of seroconversion rates using a simple, single-rate model
340 to characterize trachoma transmission. Our findings demonstrate that the slope of
341 the age-seroprevalence curve and the seroconversion rate are sensitive and
342 moderately specific markers of population-level *C. trachomatis* infection.
343 Seroprevalence is another simple, robust summary measure that aligned with
344 infections as well as seroconversion rate, particularly in the absence of recent MDA,
345 but care should be taken to ensure similar age structure between populations to
346 avoid bias.

347
348 We found that serologic summaries were sensitive indicators of *C. trachomatis*
349 infection but have only moderate specificity: antibody responses were nearly always
350 present in populations with infections, but the IgG signal persisted even if recent
351 MDA reduced infection to low levels. This pattern suggests that populations requiring
352 treatment will rarely be missed by serology but further verification with PCR could
353 prevent overtreatment in the case of false positives. Because IgG responses to Pgp3
354 are durable, age-seroprevalence curves and statistics estimated from them may
355 reflect historical transmission patterns and remain high despite low levels of infection
356 resulting from control measures or secular trends. Restricting analysis to younger
357 children (e.g., children born after discontinuing antibiotic MDA) or carefully
358 accounting for past MDA treatments in the interpretation of antibody data may
359 decrease false positives detected by IgG.

360
361 Here, we focused on IgG among young children and its relationship with *C.*
362 *trachomatis* infection to extend a previous study that combined nine trachoma
363 serology surveys and compared IgG seroconversion rates with clinical indicators
364 among people of all ages.⁴⁵ Limiting the analysis to young children rather than all
365 ages enabled us to simplify the modeling approach used to estimate seroconversion
366 rates under the assumption that transmission was approximately stable over the age
367 range. We focused on the relationship between serology and PCR infection to
368 assess the utility of serology to monitor differences in pathogen transmission.

369

370 The threshold analyses show that Pgp3 serology provides good overall
371 discrimination of the presence of *C. trachomatis* infections in a community
372 (AUC=0.92), even when limited to children 1 to 5 years old, but there are two
373 caveats to the generalizability of the thresholds estimated in this analysis. First, we
374 used clusters as the unit of analysis — a much finer spatial scale than the current
375 scale of decision making for elimination programs, which is typically at the
376 administrative district-level. We felt a similar, non-parametric threshold analysis at
377 the district (study) level would not be informative with only 11 studies that included
378 *C. trachomatis* infection measurements (**Fig. 1**), versus 281 unique clusters (**Fig. 6**).
379 Yet, the small number of children in any single cluster (median = 40) means that rare
380 infections could be missed without a larger sample size as populations approach
381 elimination (for example, if true *C. trachomatis* prevalence were 1%, then $n = 300$
382 children would need to be tested to have a 95% probability of detecting at least one
383 *C. trachomatis* infection, assuming perfect test sensitivity and independent tests,
384 where $1 - [1 - P(Ct^+)]^n \geq 0.95$). It would be rare to encounter 300 young children in
385 a single sampling cluster, so averaging over a larger spatial scale or over repeated
386 surveys in the same clusters could improve the robustness of *C. trachomatis*
387 infections as a gold standard against which serology is compared. A second caveat
388 is that the analysis included the full range of transmission settings, and lower
389 thresholds may be needed to best discriminate in low transmission settings (similar
390 to Malawi or Kongwa 2018 populations, **Fig. 6**). Building from these promising
391 results, in future work our team plans to assess serology thresholds at the district-
392 level with a focus on near-elimination and post-elimination settings.

393
394 This work is subject to limitations. First, the data we analyzed were compiled from
395 different previously published studies and sites that were available to us. Our results
396 may not be representative of all populations with ongoing trachoma transmission.
397 For example, the included studies come from five countries in Africa, but trachoma
398 continues to be endemic in the other regions of Africa, Latin America, Asia, and the
399 Pacific Islands.⁴⁸ As a secondary analysis, our work was also affected by design
400 features of individual studies, such as site selection in RCTs, which were typically
401 not selected using probability samples. Second, all models used to estimate
402 seroconversion, except for the semiparametric spline model, assumed homogeneity
403 of seroconversion rate over age and time. For most studies, we expected stable
404 transmission among 1–9-year-olds in the recent past. Our analysis used an estimate
405 of seroreversion from one longitudinal cohort,⁴⁹ but data beyond this cohort is limited
406 and seroreversion may be lower in higher transmission settings.⁵⁰ In a sensitivity
407 analysis no single seroreversion value resulted in the best model fit across
408 populations (**Supplementary Fig. 8**). Finally, we were unable to evaluate more
409 specific subgroups, such as populations with different MDA histories or populations
410 experiencing recrudescence, due to limited data. Based on the variability observed
411 between populations, refinement of thresholds may be warranted as more data are
412 collected.

413

414 In conclusion, IgG responses to *C. trachomatis* antigen Pgp3 among 1–9-year-olds
415 aligned closely with ongoing transmission as measured by PCR and TF across a
416 range of trachoma endemicity settings. Consistent with patterns observed across
417 other pathogens, age-dependent Pgp3 seroprevalence curves became flatter and
418 seroconversion rates declined to zero as populations approached elimination —
419 providing a coherent framework for monitoring *C. trachomatis* transmission in
420 seroepidemiologic studies. Serologic summaries estimated via a range of model
421 complexity were sensitive markers of ocular chlamydial infection and were consistent
422 with one another, implying that simpler approaches are likely sufficient to capture
423 variation in transmission. These results support use of serologic surveys to inform
424 trachoma programs as populations approach and achieve elimination.

425

426 **Methods**

427 **Contributing studies**

428 We gathered data from published trachoma serology surveys, with an emphasis on
429 IgG antibody responses to Pgp3 collected among children aged 1–9 years and
430 relatively recent reports (**Supplementary Table 1**). All studies were conducted
431 between 2012 and 2019. Children below the age of 1 year were excluded to mitigate
432 the influence of maternal antibodies. Based on the original study designs,
433 measurements in Matameye, Niger (PRET) and Wag Hemra, Ethiopia (TAITU) were
434 restricted to children aged under 6 years; in Dosso, Niger (MORDOR), the study was
435 limited to children aged under 5 years; and in Alefa, Andabet, Dera, and Woreta
436 town, Ethiopia, infections were measured among children aged 1–5-years, while
437 serology and TF were measured among children aged 1–9-years. For
438 measurements collected as part of a population-based surveys, multi-level cluster
439 random sampling was used. For measurements collected as part of a randomized
440 controlled trial, we combined data across arms unless otherwise noted (e.g.,
441 stratification by recent MDA). Due to changing transmission and/or control
442 interventions in studies with repeated cross-sectional data (WUHA in Wag Hemra,
443 Ethiopia; Kongwa, Tanzania from 2012-2015; MORDOR in Dosso, Niger), we
444 included only the most recent year of measurements with serology, and PCR
445 measurements if available, for each population. We excluded clusters with fewer
446 than 15 children measured to ensure sufficient information to estimate cluster level
447 means (n=22 clusters excluded, reduced from 481 to 459). Measurement sample
448 sizes reflect distinct samples from individual children.

449

450 Details of serologic, clinical, and PCR measurements can be found in the published
451 reports for each study.^{26–38} In Malawi, dried blood spots were tested for IgG
452 antibodies against Pgp3 using ELISA. Samples were added to Immulon 2HB plates
453 (Southern Biotech, Birmingham, AL, USA) pre-sensitized with Pgp3 protein and
454 incubated for two hours. After 4 washes, plates were incubated with anti-human IgG-
455 HRP (Southern Biotech) for 1 hour. Plates were then washed and incubated with
456 3,3',5,5'-tetramethylbenzidine (KPL, Gaithersburg, MD, USA). The reaction was

457 stopped with 1N H₂SO₄ and plates were read at 450 nm on a microplate reader.
458 The seropositivity cutoff was determined based on a finite mixture model.³¹ ELISA-
459 based population-level measurements of Pgp3 have been shown to have good
460 agreement with multiplex bead assays.⁵¹

461
462 In all other included studies, dried blood spots were analyzed for IgG antibodies to
463 Pgp3 using a multiplex bead assay on a Luminex platform. Briefly, Pgp3-coupled
464 beads were incubated with diluted sample for 1.5 hours, washed, and then incubated
465 with anti-human IgG (Southern Biotech, Birmingham, AL, USA) and anti-human IgG4
466 (Southern Biotech) for 45 minutes. After additional washes, beads were incubated
467 with phycoerythrin-labeled streptavidin (Invitrogen, Waltham, MA, USA) for 30
468 minutes, washed, and then incubated with phosphate buffered saline (PBS)
469 containing 0.5% BSA, 0.05% Tween-20 and 0.02% sodium azide. After a final wash,
470 beads were resuspended in 1X PBS and read on a Bio-Plex 200 instrument (Bio-
471 Rad, Hercules, CA). IgG levels were reported as median fluorescence intensity
472 minus background (MFI-bg), and seropositivity cutoffs were generated using receiver
473 operator characteristic (ROC) methods.¹⁴ We used MFI-bg cutoffs defined by each
474 study to assign seropositivity status. The MFI-bg cutoffs can vary slightly by study
475 due to differences in antigen-bead coupling efficiency in different bead sets, and
476 ranged from 882 (Kongwa, Tanzania 2013) to 1771 (Kongwa, Tanzania 2018), with
477 a median of 1558 (Alefa, Andabet, Dera, and Woreta town, Ethiopia 2017). De-
478 identified Source data provided with this study include the cutoffs used for each bead
479 set. To assess robustness to seropositivity cutoffs, we compared seroprevalence
480 and seroconversion rate calculated across a range of arbitrary cutoffs for four study
481 populations at different levels of trachoma prevalence (**Supplementary Fig. 7**),
482 which illustrate that the range over which cutoffs vary are unlikely to have a major
483 influence on seroprevalence or seroconversion rate estimates.

484
485 Clinical disease was assessed by trained field graders according to the WHO
486 simplified grading system,⁵² which defines TF as the presence of five or more
487 follicles which are (a) at least 0.5 mm in diameter and (b) located in the central part
488 of the upper tarsal conjunctiva. Conjunctival swabs were assessed for *C.*
489 *trachomatis* DNA using PCR. In five out of seven studies with PCR measurements,
490 cluster-level prevalence was estimated from individual-level results.^{29–31,35,36} In one
491 study (PRET), cluster-level prevalence was estimated from pooled results using
492 maximum likelihood methods.^{26,53} For Andabet, Dera, Woreta town, and Alefa,
493 Ethiopia, *C. trachomatis* infection prevalence was estimated at the district level from
494 pooled results using maximum likelihood methods.²⁸

495
496 Cluster-level prevalence was calculated as the number of children who were sero-,
497 PCR- or TF-positive divided by the number of children tested for the respective
498 outcome. When possible, “populations” were defined by districts or evaluation units
499 currently used for trachoma monitoring. Population-level prevalence estimates were
500 defined as the median value across clusters. Age-seroprevalence curves were

501 estimated by pooling all measurements at the population level, calculating
502 seroprevalence for one-year age groups, and fitting cubic spline models to generate
503 smooth trend lines.

504

505 **Estimating serology-based summary measures**

506 We summarized IgG responses as geometric mean IgG levels, seroprevalence, and
507 seroconversion rates from several models. The seroconversion rate from a current
508 status, single-rate catalytic model assuming no seroreversion is closely tied to the
509 slope of age-seroprevalence curve.⁵⁴ Specifically, the hazard (seroconversion rate) is
510 equal to the slope of the age-seroprevalence curve divided by the complement of the
511 seroprevalence at age $A=a$. It can be shown that the seroconversion rate based on
512 this model can be estimated as the exponentiated intercept from a generalized linear
513 model with binomial error structure and a complementary log-log link:⁵⁵

514

$$515 \log[-\log(1 - P(Y = 1 | A))] = \log(\lambda) + \log(A) \quad (1)$$

516

517 where Y represents individual level serostatus (1: seropositive, 0: seronegative or
518 equivocal), A is the child's age in years, and λ is the seroconversion rate. The
519 seroconversion rate provides an estimate of the force of infection, an epidemiological
520 parameter that denotes the rate at which susceptible individuals in the population
521 become infected.

522

523 Next, we extended this model to allow for seroreversion. Cross-sectional data do not
524 contain sufficient information to reliably estimate both seroreversion and
525 seroconversion rates.⁵⁶ Therefore, we fit a binomial maximum likelihood model for
526 seroconversion with fixed seroreversion rates ranging from 0.02 to 0.20 per person-
527 year:^{22,45}

$$528 P(Y = 1 | A) = \frac{\lambda}{\lambda + \rho} [1 - \exp(-(\lambda + \rho) \times A)] \quad (2)$$

529

530 where ρ is the assumed seroreversion rate. In our main analyses, we assumed a
531 seroreversion rate of 6.6 per 100 person-years based on a longitudinal cohort in
532 Kongwa, Tanzania monitored in the absence of MDA,⁴⁹ which is likely conservative
533 for higher transmission settings.⁵⁰ No level of seroreversion consistently provided the
534 best fit across populations (**Supplementary Fig. 8**). This model did not converge in
535 several clusters (6 out of 416 clusters with seroprevalence >0%, or 1.4%), which
536 often contained few seropositive children.

537

538 Finally, we fit semiparametric models to allow seroconversion to vary by age.⁵⁴ We fit
539 semiparametric models only at the population level, as they require more data than
540 are typically available at the sampling cluster level (around 20-40 children). We fit a
541 generalized linear model with complementary log-log link for seropositivity:

542

$$543 \log[-\log(1 - P(Y = 1 | A))] = g(A) \quad (3)$$

544 where $g(A)$ is a flexible function for age modeled using cubic splines. To estimate the
545 average seroconversion rate in each population, λ , we integrated over age using
546 predictions from the model. We used the relationship between the hazard $\lambda(a)$ and
547 cumulative incidence $F(a)$, where $F(a)$ is the predicted seroprevalence at age a
548 (details in ⁴²).

$$549 \quad \lambda = \int_{a_1}^{a_2} \lambda(a) da = \frac{\log[1-F(a_1)] - \log[1-F(a_2)]}{a_2 - a_1} \quad (4)$$

550

551 **Comparison of different trachoma indicators**

552 We used the Pearson correlation coefficient to compare serologic summaries and TF
553 prevalence with PCR prevalence at the population and cluster levels. We conducted
554 this analysis across all populations with PCR measurements and explored the
555 impact of contextual factors by stratifying clusters into subgroups defined by MDA in
556 the past year (yes / no) and age range (1–9-year-olds / 1–5-year-olds). We
557 estimated asymptotic 95% confidence intervals for study-level correlation using
558 Fisher's Z transform. To estimate 95% confidence intervals for cluster level
559 correlation estimates we used a non-parametric bootstrap (1,000 replicates) that
560 resampled clusters with replacement, stratified by study.

561

562 We used the Spearman rank correlation coefficient to compare different serologic
563 summaries with one another at the cluster level, allowing for non-linearity in the
564 relationships. We estimated simultaneous confidence intervals from a cubic spline to
565 summarize the relationship between markers at the cluster level, including a random
566 effect for study to allow for correlated measures within-study.

567

568 **Serologic thresholds for elimination**

569 We used a non-parametric approach to assess thresholds of seroprevalence or
570 seroconversion rates to classify clusters without PCR infections. For overall
571 estimates, we combined clusters from all populations with PCR measurements, for a
572 total of 281 clusters and 112 clusters with at least one PCR-detected infection. We
573 defined a range of cutoffs covering nearly all cluster-level estimates (0 to 100% for
574 seroprevalence, 0 to 50 per 100 person-years for seroconversion rate) and divided
575 the range into 200 increments. At each step, we calculated sensitivity as the
576 proportion of clusters with serology values above the threshold among clusters with
577 any infection, and specificity as the proportion of clusters with serology value less
578 than or equal to the threshold among clusters with zero infections detected. We
579 identified the highest thresholds achieving at least 90% and 80% sensitivity. We also
580 presented these results as receiver operating characteristic (ROC) curves and
581 calculated overall area-under-the-curve (AUC). We calculated sensitivity, specificity,
582 and the ROC curve for each population separately.

583

584 **Ethics and inclusion**

585 The secondary analysis protocol was reviewed and approved by the Institutional
586 Review Board at the University of California, San Francisco (Protocol #20-33198).

587 All primary data that contributed to the analysis was collected after obtaining
588 informed consent from all participants or their guardians under separate, local
589 human subjects research protocols in accordance with the Declaration of Helsinki.
590 Members from each contributing primary research study have participated as
591 collaborators and co-authors on the present analyses from their initial stages,
592 including the design, interpretation, and summary of results. Co-authors were
593 nominated by each study's principal investigator to represent the country and study
594 teams that originally contributed the data. De-identified datasets made public
595 through this analysis have been reviewed and approved by representatives from
596 each study and conform with ethical guidelines set forth in the original protocols.
597 Analyses were led by investigators at the University of California, San Francisco with
598 guidance and input from all co-authors to incorporate local stakeholder perspectives.
599

600 **Data Availability**

601 De-identified data to reproduce this work are publicly available without restriction in
602 the Open Science Framework repository, <https://osf.io/e6j5a/>.⁵⁷ Processed, de-
603 identified data generated in this study are additionally provided in the Supplementary
604 Information/Source Data file.

605

606 **Code Availability**

607 R version 4.2.2 (2022-10-21, "Innocent and Trusting") was used for this analysis.⁵⁸
608 Open source code and instructions to reproduce all analyses are available in the
609 Open Science Framework repository, <https://osf.io/e6j5a/>.⁵⁷

610

611

612

613 References

- 614 1. World Health Organization. *Ending the neglect to attain the sustainable development*
615 *goals: a roadmap for neglected tropical diseases 2021-2030.*
616 <https://apps.who.int/iris/handle/10665/361856> (2020).
- 617 2. Taylor, H. R., Burton, M. J., Haddad, D., West, S. & Wright, H. Trachoma. *The Lancet*
618 **384**, 2142–2152 (2014).
- 619 3. Keenan, J. D. *et al.* Clinical Activity and Polymerase Chain Reaction Evidence of
620 Chlamydial Infection after Repeated Mass Antibiotic Treatments for Trachoma. *Am. J.*
621 *Trop. Med. Hyg.* **82**, 482–487 (2010).
- 622 4. Amza, A. *et al.* Community-level Association between Clinical Trachoma and Ocular
623 Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of
624 Niger. *Ophthalmic Epidemiol.* **26**, 231–237 (2019).
- 625 5. Ramadhani, A. M., Derrick, T., Macleod, D., Holland, M. J. & Burton, M. J. The
626 Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection
627 before and after Mass Antibiotic Treatment. *PLoS Negl. Trop. Dis.* **10**, e0005080 (2016).
- 628 6. Assaad, F. A. & Maxwell-Lyons, F. Systematic observer variation in trachoma studies.
629 *Bull. World Health Organ.* **36**, 885–900 (1967).
- 630 7. Tielsch, J. M. *et al.* Trachoma grading: observer trials conducted in southern Malawi. *Br.*
631 *J. Ophthalmol.* **71**, 371–374 (1987).
- 632 8. Gebresillasie, S. *et al.* Inter-Rater Agreement between Trachoma Graders: Comparison
633 of Grades Given in Field Conditions versus Grades from Photographic Review.
634 *Ophthalmic Epidemiol.* **22**, 162–169 (2015).
- 635 9. Corran, P., Coleman, P., Riley, E. & Drakeley, C. Serology: a robust indicator of malaria
636 transmission intensity? *Trends Parasitol.* **23**, 575–582 (2007).
- 637 10. Stringhini, S. *et al.* Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva,
638 Switzerland (SEROCoV-POP): a population-based study. *Lancet Lond. Engl.* **396**, 313–
639 319 (2020).
- 640 11. Woodhall, S. C. *et al.* Advancing the public health applications of Chlamydia trachomatis
641 serology. *Lancet Infect. Dis.* **18**, e399–e407 (2018).
- 642 12. Martin, D. L. *et al.* The use of serology for trachoma surveillance: Current status and
643 priorities for future investigation. *PLoS Negl. Trop. Dis.* **14**, e0008316 (2020).
- 644 13. Cooley, G. M. *et al.* No Serological Evidence of Trachoma or Yaws Among Residents of
645 Registered Camps and Makeshift Settlements in Cox’s Bazar, Bangladesh. *Am. J. Trop.*
646 *Med. Hyg.* **104**, 2031–2037 (2021).
- 647 14. Goodhew, E. B. *et al.* CT694 and pgp3 as Serological Tools for Monitoring Trachoma
648 Programs. *PLoS Negl. Trop. Dis.* **6**, e1873 (2012).
- 649 15. Goodhew, E. B. *et al.* Longitudinal analysis of antibody responses to trachoma antigens
650 before and after mass drug administration. *BMC Infect. Dis.* **14**, 3154 (2014).
- 651 16. Gwyn, S. *et al.* Comparison of Platforms for Testing Antibody Responses against the
652 Chlamydia trachomatis Antigen Pgp3. *Am. J. Trop. Med. Hyg.* **97**, 1662–1668 (2017).
- 653 17. Wiegand, R. E. *et al.* Latent class modeling to compare testing platforms for detection of
654 antibodies against the Chlamydia trachomatis antigen Pgp3. *Sci. Rep.* **8**, 4232 (2018).
- 655 18. Goodhew, B. *et al.* Validation of immunoassays for the Chlamydia trachomatis antigen
656 Pgp3 using a chimeric monoclonal antibody. *Sci. Rep.* **13**, 7281 (2023).
- 657 19. Migchelsen, S. J. *et al.* Defining Seropositivity Thresholds for Use in Trachoma
658 Elimination Studies. *PLoS Negl. Trop. Dis.* **11**, e0005230 (2017).

- 659 20. Kaur, H., Dize, L., Munoz, B., Gaydos, C. & West, S. K. Evaluation of the reproducibility
660 of a serological test for antibodies to *Chlamydia trachomatis* pgp3: A potential
661 surveillance tool for trachoma programs. *J. Microbiol. Methods* **147**, 56–58 (2018).
- 662 21. Wang, J. *et al.* A Genome-Wide Profiling of the Humoral Immune Response to
663 *Chlamydia trachomatis* Infection Reveals Vaccine Candidate Antigens Expressed in
664 Humans. *J. Immunol.* **185**, 1670–1680 (2010).
- 665 22. Martin, D. L. *et al.* Serology for Trachoma Surveillance after Cessation of Mass Drug
666 Administration. *PLoS Negl. Trop. Dis.* **9**, e0003555 (2015).
- 667 23. Pant, B. P. *et al.* Control of Trachoma from Achham District, Nepal: A Cross-Sectional
668 Study from the Nepal National Trachoma Program. *PLoS Negl. Trop. Dis.* **10**, e0004462
669 (2016).
- 670 24. West, S. K. *et al.* Can We Use Antibodies to *Chlamydia trachomatis* as a Surveillance
671 Tool for National Trachoma Control Programs? Results from a District Survey. *PLoS*
672 *Negl. Trop. Dis.* **10**, e0004352 (2016).
- 673 25. Arnold, B. F., Scobie, H. M., Priest, J. W. & Lammie, P. J. Integrated Serologic
674 Surveillance of Population Immunity and Disease Transmission. *Emerg. Infect. Dis.* **24**,
675 1188–1194 (2018).
- 676 26. Amza, A. *et al.* A Cluster-Randomized Trial to Assess the Efficacy of Targeting
677 Trachoma Treatment to Children. *Clin. Infect. Dis.* **64**, 743–750 (2017).
- 678 27. Kim, J. S. *et al.* Community-level chlamydial serology for assessing trachoma elimination
679 in trachoma-endemic Niger. *PLoS Negl. Trop. Dis.* **13**, e0007127 (2019).
- 680 28. Nash, S. D. *et al.* Population-Based Prevalence of *Chlamydia trachomatis* Infection and
681 Antibodies in Four Districts with Varying Levels of Trachoma Endemicity in Amhara,
682 Ethiopia. *Am. J. Trop. Med. Hyg.* **104**, 207–215 (2021).
- 683 29. Wilson, N. *et al.* Evaluation of a Single Dose of Azithromycin for Trachoma in Low-
684 Prevalence Communities. *Ophthalmic Epidemiol.* **26**, 1–6 (2019).
- 685 30. Odonkor, M. *et al.* Serology, infection, and clinical trachoma as tools in prevalence
686 surveys for re-emergence of trachoma in a formerly hyperendemic district. *PLoS Negl.*
687 *Trop. Dis.* **15**, e0009343 (2021).
- 688 31. Burr, S. E. *et al.* Pgp3 seroprevalence and associations with active trachoma and ocular
689 *Chlamydia trachomatis* infection in Malawi: cross-sectional surveys in six evaluation
690 units. *PLoS Negl. Trop. Dis.* **13**, e0007749 (2019).
- 691 32. Hammou, J. *et al.* Post-Validation Survey in Two Districts of Morocco after the
692 Elimination of Trachoma as a Public Health Problem. *Am. J. Trop. Med. Hyg.* **106**,
693 1370–1378 (2022).
- 694 33. Hammou, J. *et al.* In Morocco, the elimination of trachoma as a public health problem
695 becomes a reality. *Lancet Glob. Health* **5**, e250–e251 (2017).
- 696 34. Wittberg, D. M. *et al.* WASH Upgrades for Health in Amhara (WUHA): study protocol for
697 a cluster-randomised trial in Ethiopia. *BMJ Open* **11**, e039529 (2021).
- 698 35. Melo, J. S. *et al.* Targeted Antibiotics for Trachoma: A Cluster-Randomized Trial. *Clin.*
699 *Infect. Dis.* **73**, 979–986 (2021).
- 700 36. Arague, S. *et al.* Water, sanitation, and hygiene for control of trachoma in Ethiopia
701 (WUHA): a two-arm, parallel-group, cluster-randomised trial. *Lancet Glob. Health* **10**,
702 e87–e95 (2022).
- 703 37. Arzika, A. M. *et al.* Effect of biannual azithromycin distribution on antibody responses to
704 malaria, bacterial, and protozoan pathogens in Niger. *Nat. Commun.* **13**, 976 (2022).

- 705 38. Arzika, A. M. *et al.* Effect of Biannual Mass Azithromycin Distributions to Preschool-Aged
706 Children on Trachoma Prevalence in Niger: A Cluster Randomized Clinical Trial. *JAMA*
707 *Netw. Open* **5**, e2228244 (2022).
- 708 39. Solomon, A. W. *et al.* Trachoma. *Nat. Rev. Dis. Primer* **8**, 1–20 (2022).
- 709 40. Arnold, B. F. *et al.* Measuring changes in transmission of neglected tropical diseases,
710 malaria, and enteric pathogens from quantitative antibody levels. *PLoS Negl. Trop. Dis.*
711 **11**, e0005616 (2017).
- 712 41. Tedijanto, C. *et al.* Predicting future community-level ocular *Chlamydia trachomatis*
713 infection prevalence using serological, clinical, molecular, and geospatial data. *PLoS*
714 *Negl. Trop. Dis.* **16**, e0010273 (2022).
- 715 42. Arnold, B. F. *et al.* Fine-scale heterogeneity in *Schistosoma mansoni* force of infection
716 measured through antibody response. *Proc. Natl. Acad. Sci.* **117**, 23174–23181 (2020).
- 717 43. Amoah, B. *et al.* Model-based geostatistics enables more precise estimates of neglected
718 tropical-disease prevalence in elimination settings: mapping trachoma prevalence in
719 Ethiopia. *Int. J. Epidemiol.* **51**, 468–478 (2022).
- 720 44. Arnold, B. F. *et al.* Measuring changes in transmission of neglected tropical diseases,
721 malaria, and enteric pathogens from quantitative antibody levels. *PLoS Negl. Trop. Dis.*
722 **11**, e0005616 (2017).
- 723 45. Pinsent, A. *et al.* The utility of serology for elimination surveillance of trachoma. *Nat.*
724 *Commun.* **9**, 5444 (2018).
- 725 46. Yman, V. *et al.* Antibody acquisition models: A new tool for serological surveillance of
726 malaria transmission intensity. *Sci. Rep.* **6**, 19472 (2016).
- 727 47. Sepúlveda, N., Stresman, G., White, M. T. & Drakeley, C. J. Current Mathematical
728 Models for Analyzing Anti-Malarial Antibody Data with an Eye to Malaria Elimination and
729 Eradication. *J. Immunol. Res.* **2015**, 1–21 (2015).
- 730 48. Renneker, K. K. *et al.* Global progress toward the elimination of active trachoma: an
731 analysis of 38 countries. *Lancet Glob. Health* **10**, e491–e500 (2022).
- 732 49. West, S. K. *et al.* Longitudinal change in the serology of antibodies to *Chlamydia*
733 *trachomatis* pgp3 in children residing in a trachoma area. *Sci. Rep.* **8**, 3520 (2018).
- 734 50. Tedijanto, C. *et al.* Seroreversion to *Chlamydia trachomatis* Pgp3 antigen among young
735 children in a hyperendemic region of Amhara, Ethiopia. *MedRxiv Prepr.*
736 2023.02.04.23285360 (2023) doi:10.1101/2023.02.04.23285360.
- 737 51. Gwyn, S. *et al.* The Performance of Immunoassays to Measure Antibodies to the
738 *Chlamydia trachomatis* Antigen Pgp3 in Different Epidemiological Settings for
739 Trachoma. *Am. J. Trop. Med. Hyg.* (2021) doi:10.4269/ajtmh.21-0541.
- 740 52. Thylefors, B., Dawson, C. R., Jones, B. R., West, S. K. & Taylor, H. R. A simple system
741 for the assessment of trachoma and its complications. *Bull. World Health Organ.* **65**,
742 477–483 (1987).
- 743 53. Ray, K. J. *et al.* Estimating Community Prevalence of Ocular *Chlamydia trachomatis*
744 Infection using Pooled Polymerase Chain Reaction Testing. *Ophthalmic Epidemiol.* **21**,
745 86–91 (2014).
- 746 54. Hens, N., Shkedy, Z., Aerts, M., Damme, C. F. P. V. & Beutels, P. *Modeling Infectious*
747 *Disease Parameters Based on Serological and Social Contact Data.* (Springer, 2012).
- 748 55. Jewell, N. P. & Laan, M. V. Generalizations of current status data with applications.
749 *Lifetime Data Anal.* **1**, 101–109 (1995).
- 750 56. Arnold, B. F. *et al.* Enteropathogen antibody dynamics and force of infection among
751 children in low-resource settings. *eLife* **8**, e45594 (2019).

- 752 57. Arnold, B. F. & Tedijanto, C. Monitoring transmission intensity of trachoma with serology:
753 source data and code. (2023) doi:10.17605/OSF.IO/E6J5A.
754 58. R Core Team. *R: A language and environment for statistical computing*. (R Foundation
755 for Statistical Computing, 2020).

756
757

758 **Acknowledgements**

759 *Funding statement.* This work was supported by the National Institute of Allergy and
760 Infectious Diseases (R01-AI158884 to B.F.A.).

761

762 *Disclaimer.* The findings and conclusions in this article are those of the authors and
763 do not necessarily represent the official position of the National Institutes of Health or
764 the Centers for Disease Control and Prevention. Use of trade names is for
765 identification only and does not imply endorsement by the Public Health Service or
766 by the U.S. Department of Health and Human Services. The authors alone are
767 responsible for the views expressed in this article, and they do not necessarily
768 represent the views, decisions, or policies of the institutions with which they are
769 affiliated. AWS is a staff member of the World Health Organization.

770

771 **Author Contributions**

772 Following [CRediT taxonomy](#): conceptualization (CT, AWS, DLM, SDN, PJJ, BFA),
773 data curation (CT, DLM, BFA), formal analysis (CT, BFA), funding acquisition (BFA,
774 DLM), investigation (CT, BFA), methodology (CT, BFA), project administration (DLM,
775 BFA), resources (all authors), software (CT, BFA), supervision (AWS, DLM, SDN,
776 SKW, TML, JDK, PJJ), validation (CT, BG, DLM, BFA), visualization (CT, BFA),
777 writing - original draft preparation (CT, BFA), writing - review & editing (all authors)


778

779 **Competing Interests**

780 The authors declare no competing interests.

781

782




* Estimates collected in population based survey
 † Serology, PCR, and TF measured among 1-5 year olds only
 ‡ PCR prevalence measured only at the district-level among 1-5 year olds

783

784

785 **Figure 1. Seroprevalence, PCR positivity, and TF prevalence across study populations.**

786 Cluster-level prevalence estimates are represented by colored lines, and overlaid boxplots
 787 show the median, interquartile range, and range (excluding outliers defined as points more
 788 than 1.5 times the interquartile range from the 25th or 75th percentile) for each population.
 789 Study site, country, study name (if applicable), and year of data collection are listed on the left
 790 with number of individuals (n) and number of clusters (m) included in the analyses. For studies
 791 with only district-level estimates of PCR prevalence the mean is indicated with a circle rather
 792 than box plot. NA marks studies that did not measure PCR or trachomatous inflammation—
 793 follicular (TF). Study populations are arranged in descending order of seroconversion rates,
 794 presented in Figure 2. Source data are provided with this paper. Created with notebook
 795 <https://osf.io/qjst8> .



796

797

798

799

800

801

802

803

804

805

806

807

808

809

810


811

812

813

Figure 2. Age-dependent seroprevalence curves, modeled seroconversion rates, and PCR prevalence across study populations. Cubic splines fit to seroprevalence by age are shown in the left plot. Cluster-level seroconversion rates and PCR prevalence estimates are represented by colored lines, and overlaid boxplots show the median, interquartile range, and range (excluding outliers defined as points more than 1.5 times the interquartile range from the 25th or 75th percentile) for each population. Figure 1 includes each study's sample size. Study populations are arranged in descending order of median seroconversion rate assuming no seroreversion. *C. trachomatis* PCR measurements are identical to Figure 1 and are included for reference. For studies with only district-level estimates of PCR prevalence, the mean is indicated with a circle rather than box plot. NA indicates that a study did not measure *C. trachomatis* infections with PCR. Abbreviations: PY = person-years; ETH = Ethiopia; MAR = Morocco; MWI = Malawi; NER = Niger; TZA = Tanzania. Source data are provided with this paper. Created with notebook <https://osf.io/rghyc>.

814



815

816

817

818

819

820

821

822

823

824

825

826

827


828

829

830

Figure 3. Relationship between different cluster-level serologic summary measures. a Geometric mean IgG response versus seroprevalence. **b** Seroconversion rate versus seroprevalence. **c** Seroconversion rate allowing for seroreversion versus a seroconversion rate that assumes no seroreversion. **d** Seroconversion rate that assumes seroreversion versus seroprevalence. Spearman rank correlations across sampling clusters are shown for each comparison. In all panels, small points represent cluster-level estimates and medians for each study population are represented by larger points with black outline. Shaded bands show simultaneous 95% confidence intervals for a spline fit through cluster-level estimates. A fixed seroreversion rate of 6.6 per 100 person-years was assumed in the catalytic model allowing for seroreversion (Methods). Figure 1 includes each study's sample size (median cluster size = 40 children). Abbreviations: PY = person-years; ETH = Ethiopia; MAR = Morocco; MWI = Malawi; NER = Niger; TZA = Tanzania. Source data are provided with this paper. Created with notebook <https://osf.io/wcv86>.

831



832

833

834

835

836

837

838

839

840

841

842

843

844

845


846

847

848

Figure 4. Relationship between trachoma biomarkers in the presence and absence of recent mass distribution of azithromycin (MDA). **a** Correlations between cluster PCR prevalence and seroprevalence overall and stratified by whether the study population had received MDA in the previous year. **b** Correlations between PCR prevalence and TF prevalence overall and stratified by whether the study population had received MDA in the previous year. In all panels, medians across clusters for each study population are represented by larger points with black outline. Each plot includes the identity line (dotted) and Pearson correlations at the cluster- and population-levels. 95% confidence intervals (CIs) are based on 1,000 bootstrapped samples, holding populations fixed and resampling clusters with replacement. Population-level estimates are included for Andabet, Dera, Woreta town, and Alefa, Ethiopia, but cluster-level PCR prevalence was not available for these populations. Figure 1 includes each study's sample size. Abbreviations: ETH = Ethiopia; MWI = Malawi; NER = Niger; TZA = Tanzania. Source data are provided with this paper. Created with notebook <https://osf.io/rt825>.

849




850

851

852 **Figure 5. Relationship between trachoma biomarkers in different monitoring age**
 853 **ranges. a** Correlations between cluster PCR prevalence and seroprevalence overall and
 854 stratified by age of monitoring population. **b** Correlations between *C. trachomatis* PCR
 855 prevalence and TF prevalence overall and stratified by age of monitoring population. In all
 856 panels, medians across clusters for each study population are represented by larger points
 857 with black outline. Each plot includes the identity line (dotted) and Pearson correlations at the
 858 cluster- and population-levels. 95% confidence intervals (CIs) are based on 1,000
 859 bootstrapped samples, holding populations fixed and resampling clusters with replacement.
 860 Population-level estimates are included for Andabet, Dera, Woreta town, and Alefa, Ethiopia,
 861 but cluster-level PCR prevalence was not available for these populations. Figure 1 includes
 862 each study's sample size. Abbreviations: ETH = Ethiopia; MWI = Malawi; NER = Niger; TZA
 863 = Tanzania; TF = trachomatous inflammation—follicular. Source data are provided with this
 864 paper. Created with notebook <https://osf.io/rt825>.

865

866



867
868

869 **Figure 6. Identification of clusters with *C. trachomatis* infection using seroprevalence.**

870 **a** Sensitivity and specificity curves for identification of clusters with any *C. trachomatis* PCR
871 infections based on different seroprevalence thresholds among children 1-9 years old (n =
872 281 clusters, 112 clusters with PCR>0%). Vertical lines delineate sensitivity at 90% (solid
873 line, 13.5% seroprevalence) and 80% (dotted line, 22.5% seroprevalence). Thin lines show
874 sensitivity for each study population with cluster-level PCR measurements. Points at the
875 bottom of the panel mark seroprevalence estimates for each study population. **b** Receiver
876 operating characteristic (ROC) curves for all clusters (thick black line) and for each study
877 population (thin colored lines) with overall area-under-the-curve (AUC). Note that the ROC
878 curve for Kongwa, TZA 2013 lies beneath the curve for Wag Hemra, ETH (WUHA). Figure 1
879 includes each study's sample size. Abbreviations: ETH = Ethiopia; MWI = Malawi; NER =
880 Niger; TZA = Tanzania. Supplementary Data 1 includes underlying sensitivity and specificity
881 values at each cutoff. Source data are provided with this paper. Created with notebook
882 <https://osf.io/vgekh> .

883